Immune Checkpoint Inhibitors for Recurrent Hepatocellular Carcinoma After Liver Transplantation: Safety Under an Immunosuppression-Preserving Strategy

Shih-Chao Hsu; Sheng-Hsien Chen; Te-Hong Chen; Wei-Fan Hsu; Hung-Wei Wang; Chun-Chieh Yeh; Horng-Ren Yang; Hsueh-Chou Lai; Long-Bin Jeng

doi:10.12659/AOT.952135

24 March 2026 : Original article

Immune Checkpoint Inhibitors for Recurrent Hepatocellular Carcinoma After Liver Transplantation: Safety Under an Immunosuppression-Preserving Strategy

Shih-Chao Hsu^{ABCDEF 1,2*}, Sheng-Hsien Chen^{AE 1,2}, Te-Hong Chen^{AE 1,2}, Wei-Fan Hsu^{AE 3}, Hung-Wei Wang^{AE 3,4}, Chun-Chieh Yeh^{AE 1,2,3,5}, Horng-Ren Yang^{AE 1,2}, Hsueh-Chou Lai^{AE 3}, Long-Bin Jeng^{AE 1,2}

DOI: 10.12659/AOT.952135

Ann Transplant 2026; 31:e952135

Authors information Article notes Copyright and License information

Introduction Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Figure 2 Kaplan-Meier progression-free survival (PFS) according to (A) recurrence timing, (B) alpha-fetoprotein (AFP) level, and (C) steroid use in post–liver transplant patients treated with immune checkpoint inhibitors (ICIs).

Back to the Article

Immune Checkpoint Inhibitors for Recurrent Hepatocellular Carcinoma After Liver Transplantation: Safety Under an Immunosuppression-Preserving Strategy

Your Privacy